Descartes-08 is a cell therapy wherein T-cells are modified to attack myeloma cells. To modify the cells, new instructions (called RNA) are inserted into the T-cells. These RNA instructions cause the CAR in Descartes-08 T-cells to kill other cells that carry a marker called BCMA. Because the BCMA marker is present on myeloma cells, it is hoped that Decartes-08 will destroy the myeloma cells without harming most other cell types.
Descartes-08 CAR-T cells are altered with RNA, which has a defined half-life. This allows the cells to be administered repetitively in large numbers to kill myeloma cells. It also allows CAR T-cell numbers in the body to be predictable and controlled, potentially reducing risk of side effects.
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
There are no resources, links or videos to display for this treatment.